TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25667206

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 1000 mg, two doses
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 30
Study: 25667274

Group type: EXPERIMENTAL
Intervention: erlotinib for EGFR mutations
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: selumetinib for KRAS, NRAS, HRAS, or BRAF mutations
Number of subjects: 647

Group type: COMPARATOR
Intervention: Standard-of-care therapies or biomarker-matched treatment groups
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 647
Study: 25667281

Group type: EXPERIMENTAL
Intervention: Image-Guided Radiation Therapy (IGRT)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Preoperative radiation therapy without IGRT (from CAN-NCIC-SR2 trial)
Number of subjects: 79
Study: 25667295

Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg
Number of subjects: 1861

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 1861

Group type: EXPERIMENTAL
Intervention: Ipilimumab (combined data from expanded access program)
Number of subjects: 1861
Study: 25667973

Group type: EXPERIMENTAL
Intervention: HPV16
Number of subjects: 40901

Group type: EXPERIMENTAL
Intervention: HPV31
Number of subjects: 40901

Group type: EXPERIMENTAL
Intervention: HPV52
Number of subjects: 40901

Group type: EXPERIMENTAL
Intervention: HPV18
Number of subjects: 40901

Group type: EXPERIMENTAL
Intervention: HPV16 and HPV18
Number of subjects: 40901
Study: 25668820

Group type: EXPERIMENTAL
Intervention: Stable antiretroviral therapy
Number of subjects: 147
Study: 25669310

Group type: EXPERIMENTAL
Intervention: Dietary cysteine intake (mean, 635 mg/d)
Number of subjects: 34250

Group type: EXPERIMENTAL
Intervention: Dietary intake of other amino acids
Number of subjects: 34250
Study: 25669662

Group type: EXPERIMENTAL
Intervention: Pilaralisib 400 mg plus erlotinib 150 mg
Number of subjects: 35
Study: 25669746

Group type: EXPERIMENTAL
Intervention: bapineuzumab treatment
Number of subjects: 262

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: antithrombotic agents
Number of subjects: 262
Study: 25669829

Group type: EXPERIMENTAL
Intervention: Pazopanib and vorinostat
Number of subjects: 78
Study: 25670018

Group type: EXPERIMENTAL
Intervention: [(99m)Tc]Tilmanocept (50 µg, radiolabeled with either 0.5 mCi same day or 2.0 mCi next day)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: [(99m)Tc]Tilmanocept
Number of subjects: 101
Study: 25670231

Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide (NT pro-BNP)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: high-sensitivity CRP (hsCRP)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: cystatin C (CysC)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: myeloperoxidase (MPO)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: high-sensitivity troponin I (hsTnI)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: von Willebrand factor (VWF)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: SYNTAX score
Number of subjects: 635
Study: 25670894

Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonsmoking controls
Number of subjects: 100

Group type: COMPARATOR
Intervention: Current or ex-smoking controls
Number of subjects: 100
Study: 25670896

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formoterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: As-needed short-acting β2-agonist (salbutamol)
Number of subjects: 0
Study: 25671113

Group type: EXPERIMENTAL
Intervention: School garden intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 12
Study: 25671576

Group type: EXPERIMENTAL
Intervention: PLIÉ
Number of subjects: 12

Group type: COMPARATOR
Intervention: UC
Number of subjects: 12
Study: 25671593

Group type: EXPERIMENTAL
Intervention: Cell phones and Internet for participant tracking
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Texting as a communication tool
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Internet searches (Google, paid databases, etc.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Social media for participant tracking
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Overall use of technology for participant tracking
Number of subjects: 21
Study: 25672429

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise training, performed 3 times per week for 3 months.
Number of subjects: 123

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 123
Study: 25672894

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide for 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaled budesonide and Placebo
Number of subjects: 0
Study: 25672916

Group type: EXPERIMENTAL
Intervention: Buparlisib (50, 80, and 100 mg/day) plus carboplatin AUC 5 and paclitaxel 175 mg/m(2) on day 1 of a 21-day cycle with pegfilgrastim support (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Buparlisib (50, 80, and 100 mg/day) plus carboplatin AUC 5 and paclitaxel 80 mg/m(2) on days 1, 8, and 15 of a 28-day cycle without growth factor support (Group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Buparlisib plus carboplatin + paclitaxel
Number of subjects: 30
Study: 25674045

Group type: EXPERIMENTAL
Intervention: Volunteer telephone smoking cessation counseling follow-up (2-4 times)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Volunteer telephone smoking cessation counseling follow-up (0-1 times)
Number of subjects: 131
Study: 25674536

Group type: EXPERIMENTAL
Intervention: Cisplatin-vinorelbine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: mRNA and miRNA predictive signatures
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: mRNA and miRNA prognostic signatures
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Validation of signatures
Number of subjects: 60
Study: 25675863

Group type: EXPERIMENTAL
Intervention: BCR-ABL1+ ALLs with high CDK4 expression, phosphorylated pRb (p-pRb), and telomerase activity
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Enhanced p16(INK4A) expression in BCR-ABL1+ ALLs
Number of subjects: 123

Group type: COMPARATOR
Intervention: Philadelphia chromosome-negative/IKAROS-deleted (BCR-ABL1(-)/IKAROS(del)) cases
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: In vitro analyses of normal stimulated lymphocytes
Number of subjects: 123
Study: 25676000

Group type: EXPERIMENTAL
Intervention: Baseline statin use
Number of subjects: 10418

Group type: COMPARATOR
Intervention: Aspirin use
Number of subjects: 10418
Study: 25676427

Group type: EXPERIMENTAL
Intervention: Genetic research findings related to alopecia areata
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New therapeutic strategies
Number of subjects: 0
Study: 25677599

Group type: EXPERIMENTAL
Intervention: Timed Up and Go test
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Berg Balance Scale
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Gait speed
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Dual-task walking performance
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Timed Up and Go times >12 s at 6 months
Number of subjects: 298
Study: 25677668

Group type: EXPERIMENTAL
Intervention: Ziv-aflibercept (1.25 mg, 0.05 mL intravitreal injection)
Number of subjects: 6
Study: 25677851

Group type: EXPERIMENTAL
Intervention: High-risk group (detectable TnT ≥0.01 ng/mL and BNP >440 pg/mL)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Intermediate-risk group (either detectable TnT or high BNP)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Low-risk group (nondetectable TnT and low BNP)
Number of subjects: 267
Study: 25678046

Group type: EXPERIMENTAL
Intervention: Cognitive impairment (self-reported)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No cognitive impairment (control)
Number of subjects: 28
Study: 25678143

Group type: EXPERIMENTAL
Intervention: cART
Number of subjects: 117
Study: 25678281

Group type: EXPERIMENTAL
Intervention: FIREHAWK stent
Number of subjects: 1007
Study: 25678411

Group type: EXPERIMENTAL
Intervention: Failure of central venous catheter (CVC) removal in Group 1
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Hypoalbuminaemia in Group 1
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Failure of central venous catheter (CVC) removal in Group 2
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation in Group 2
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Hypoalbuminaemia in Group 2
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Neutropaenia in Group 2
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Male gender in Group 2
Number of subjects: 248
Study: 25678831

Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin (PRM) nightly for 6 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo nightly for 6 weeks
Number of subjects: 13
Study: 25679067

Group type: EXPERIMENTAL
Intervention: G + nP + T (gemcitabine + nab-paclitaxel + TH-302)
Number of subjects: 4

Group type: COMPARATOR
Intervention: G + nP (gemcitabine + nab-paclitaxel)
Number of subjects: 4

Group type: COMPARATOR
Intervention: T (TH-302)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Vehicle (V)
Number of subjects: 4
Study: 25679107

Group type: EXPERIMENTAL
Intervention: Early peripheral perfusion-guided fluid therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25679125

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment for 6 months
Number of subjects: 589
Study: 25679358

Group type: EXPERIMENTAL
Intervention: Third-degree OASI (type 3a and 3b)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Fourth-degree OASI
Number of subjects: 343
Study: 25679914

Group type: EXPERIMENTAL
Intervention: Auditory brainstem response using brainstem audiometry
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 48
Study: 25679979

Group type: EXPERIMENTAL
Intervention: Maternal hand washing with soap
Number of subjects: 3045

Group type: EXPERIMENTAL
Intervention: Improved sanitation facilities
Number of subjects: 3045

Group type: EXPERIMENTAL
Intervention: Post-primary education of mothers
Number of subjects: 3045

Group type: EXPERIMENTAL
Intervention: Malnutrition in children from impoverished households
Number of subjects: 3045

Group type: EXPERIMENTAL
Intervention: Seasonal variation (winter vs summer)
Number of subjects: 3045
Study: 25680307

Group type: EXPERIMENTAL
Intervention: ProMRI Pacemaker System
Number of subjects: 272
Study: 25680594

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) plus cetuximab (400 mg/m² on day -7 and then 250 mg/m² on days 0 and +8)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) plus cetuximab
Number of subjects: 50
Study: 25681380

Group type: EXPERIMENTAL
Intervention: Baseline resistance (4.2% in subcohort, 7.1% overall)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Subtype C infection
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Non-B/C subtype infection
Number of subjects: 466
Study: 25681417

Group type: EXPERIMENTAL
Intervention: Resting GLS <|9|%
Number of subjects: 202

Group type: COMPARATOR
Intervention: Resting GLS >|9|%
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Stress GLS <|10|%
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Stress GLS
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Rest GLS
Number of subjects: 202
Study: 25681854

Group type: EXPERIMENTAL
Intervention: Second laparoscopic surgery for recurrent unilateral endometriomas (n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no recurrence and no second surgery, n = 18)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both study groups (primary surgery)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Case subjects after second surgery
Number of subjects: 36
Study: 25682339

Group type: EXPERIMENTAL
Intervention: Index lesion ablation using high-intensity focused ultrasound
Number of subjects: 56
Study: 25682485

Group type: EXPERIMENTAL
Intervention: Everolimus (0.1 mg orally once daily)
Number of subjects: 3
Study: 25682595

Group type: EXPERIMENTAL
Intervention: Hyper-CVAD regimen (cyclophosphamide, vincristine, Adriamycin, and dexamethasone) with imatinib
Number of subjects: 54
Study: 25682597

Group type: EXPERIMENTAL
Intervention: PR104 (dose ranged from 1.1 to 4 g/m(2))
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PR104 (3 g/m(2) or 4 g/m(2))
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PR104 administration
Number of subjects: 50
Study: 25682854

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Atypical depressive symptoms
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Age at onset
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Number of suicide attempts
Number of subjects: 289

Group type: COMPARATOR
Intervention: No rapid cycling
Number of subjects: 289
Study: 25683285

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day
Number of subjects: 507
Study: 25683846

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.2 mg/kg weekly on days 1, 8, and 15 for two 28-day cycles)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Augmented ICE (augICE) after brentuximab vedotin for PET-positive patients
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Overall treatment (brentuximab vedotin followed by augICE)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 45
Study: 25684041

Group type: EXPERIMENTAL
Intervention: Neoadjuvant denosumab
Number of subjects: 0
Study: 25684279

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV) administered under medical supervision
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 282
Study: 25684479

Group type: EXPERIMENTAL
Intervention: Cancer survivors post cancer directed therapy (CDT)
Number of subjects: 31
Study: 25684587

Group type: EXPERIMENTAL
Intervention: Saturation-based media campaigns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost per disability-adjusted life-year
Number of subjects: 0
Study: 25685162

Group type: EXPERIMENTAL
Intervention: Timothy grass sublingual immunotherapy tablet 2800 BAU
Number of subjects: 386
Study: 25685352

Group type: EXPERIMENTAL
Intervention: Common Mental Disorders Questionnaire (CMDQ) administered 12 months post-operation and again 14 days later.
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Common Mental Disorders Questionnaire (CMDQ) administered 12 months post-operation.
Number of subjects: 49
Study: 25685360

Group type: EXPERIMENTAL
Intervention: Simvastatin/Ezetimibe
Number of subjects: 1620

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1620
Study: 25685703

Group type: EXPERIMENTAL
Intervention: Resting-state functional MRI (rs-fMRI) connectivity measures
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Behavioral measures
Number of subjects: 118

Group type: COMPARATOR
Intervention: rs-fMRI data
Number of subjects: 118
Study: 25685872

Group type: EXPERIMENTAL
Intervention: Normal GFR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced GFR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low GFR
Number of subjects: 0
Study: 25686166

Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure (SBP) of 130 to 139 mm Hg
Number of subjects: 3708

Group type: EXPERIMENTAL
Intervention: Time-updated systolic blood pressure (SBP) of 130 to 139 mm Hg
Number of subjects: 3708

Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure (SBP) of 140 mm Hg or greater
Number of subjects: 3708

Group type: EXPERIMENTAL
Intervention: Time-updated systolic blood pressure (SBP) of 140 mm Hg or greater
Number of subjects: 3708

Group type: EXPERIMENTAL
Intervention: Time-updated SBP greater than 130 mm Hg
Number of subjects: 3708
Study: 25687533

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160mg/d
Number of subjects: 67
Study: 25687566

Group type: EXPERIMENTAL
Intervention: Cervicovaginal fluid (CVF) IL-6 ≥463 pg/mL
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: 3-marker CVF model (IL-6 + CXCL1 + insulin-like growth factor binding protein-1)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: 2-marker models (IL-6 + CXCL1 or alpha fetoprotein + CXCL1)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: MIAC presence
Number of subjects: 414
Study: 25687867

Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice a day (days 1 to 21) with cisplatin 80 mg/m(2) (day 1) and capecitabine 1,000 mg/m(2) twice a day (days 1 to 14) in 21-day cycles
Number of subjects: 22
Study: 25688511

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 44
Study: 25690384

Group type: EXPERIMENTAL
Intervention: Inverted grayscale rib series
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Double-modality method (conventional + inverted grayscale rib series)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional rib series
Number of subjects: 110
Study: 25690605

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25690834

Group type: EXPERIMENTAL
Intervention: Goal-Directed Fluid Therapy (GDFT) using closed-loop fluid administration system with non-invasive cardiac output monitoring (Nexfin™)
Number of subjects: 13
Study: 25692527

Group type: EXPERIMENTAL
Intervention: Global coronary artery plaque area
Number of subjects: 108

Group type: COMPARATOR
Intervention: Coronary artery stenosis ≥50%
Number of subjects: 108

Group type: COMPARATOR
Intervention: Artery tortuosity
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Global coronary plaque area
Number of subjects: 108
Study: 25692692

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 7641

Group type: EXPERIMENTAL
Intervention: High-intensity statin (atorvastatin ≥40 mg/day or rosuvastatin ≥20 mg/day)
Number of subjects: 7641

Group type: EXPERIMENTAL
Intervention: Lipid control
Number of subjects: 7641
Study: 25693010

Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin
Number of subjects: 130302
Study: 25693138

Group type: EXPERIMENTAL
Intervention: 3M SpotOn sensor (zero heat flux method)
Number of subjects: 83
Study: 25693419

Group type: EXPERIMENTAL
Intervention: FRAT-up web-based fall-risk assessment tool
Number of subjects: 0
Study: 25693610

Group type: EXPERIMENTAL
Intervention: HealthPROMISE app
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (patient education app)
Number of subjects: 300
Study: 25694653

Group type: EXPERIMENTAL
Intervention: LPV/r monotherapy (400/100 mg twice daily)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: LPV/r monotherapy with FTC/TDF intensification as needed
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: LPV/r monotherapy
Number of subjects: 123
Study: 25695490

Group type: EXPERIMENTAL
Intervention: Decursin (D) 119 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Decursinol angelate (DA) 77 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Decursinol (DOH) (metabolite)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Decursin (D)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Decursinol angelate (DA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Decursinol (DOH)
Number of subjects: 20
Study: 25696001

Group type: EXPERIMENTAL
Intervention: EGFRvIII-directed CAR T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lead candidate scFv CAR-transduced T cells
Number of subjects: 0
Study: 25696062

Group type: EXPERIMENTAL
Intervention: Sedentary behavior (<100 accelerometry counts/min)
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: Physical activity (100 to 499 accelerometry counts/min)
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: Physical activity (≥500 accelerometry counts/min)
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: Mean counts per minute of daily PA
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: Counts per minute of daily PA (sex-specific)
Number of subjects: 1170
Study: 25696919

Group type: EXPERIMENTAL
Intervention: Entospletinib (GS-9973) 800 mg twice daily
Number of subjects: 41
Study: 25697988

Group type: EXPERIMENTAL
Intervention: Real-time, ultrasound-guided infraclavicular axillary vein cannulation
Number of subjects: 29
Study: 25698370

Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (125 mg/week) with methotrexate (6-8 mg/week) for 52 weeks
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (125 mg/week) with methotrexate (6-8 mg/week)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (125 mg/week)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Self-injection of subcutaneous abatacept
Number of subjects: 112
Study: 25698651

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training regimen (30 min per session, 3 times per week for 10 weeks, target heart rate of 70-80% of heart rate reserve)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training regimen
Number of subjects: 13
Study: 25698905

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 9468

Group type: COMPARATOR
Intervention: No statin use
Number of subjects: 9468
Study: 25699246

Group type: EXPERIMENTAL
Intervention: Novel brain and vestibular rehabilitation treatment for PTSD
Number of subjects: 98
Study: 25699616

Group type: EXPERIMENTAL
Intervention: mobile contingency management (mCM)
Number of subjects: 20
Study: 25700037

Group type: EXPERIMENTAL
Intervention: Intracoronary cell therapy
Number of subjects: 1252
Study: 25700319

Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation for coronary patients (C)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Outpatient rehabilitation for noncoronary patients (NC)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Outpatient rehabilitation for both coronary (C) and noncoronary (NC) patients
Number of subjects: 63
Study: 25700617

Group type: EXPERIMENTAL
Intervention: iPhone-based remote control system for CT reading
Number of subjects: 120

Group type: COMPARATOR
Intervention: LCD monitor for CT reading
Number of subjects: 120
Study: 25700748

Group type: EXPERIMENTAL
Intervention: CT-RECTOR score for predicting successful guidewire crossing
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: CT-RECTOR score
Number of subjects: 240
Study: 25700755

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) with a self-expanding bioprosthesis
Number of subjects: 471